[go: up one dir, main page]

BR8901711A - Aperfeicoamento no processo para a polimerizacao em leito fluido de alfaolefinas - Google Patents

Aperfeicoamento no processo para a polimerizacao em leito fluido de alfaolefinas

Info

Publication number
BR8901711A
BR8901711A BR898901711A BR8901711A BR8901711A BR 8901711 A BR8901711 A BR 8901711A BR 898901711 A BR898901711 A BR 898901711A BR 8901711 A BR8901711 A BR 8901711A BR 8901711 A BR8901711 A BR 8901711A
Authority
BR
Brazil
Prior art keywords
alpholefins
polymerization
improvement
fluid bed
potentiating
Prior art date
Application number
BR898901711A
Other languages
English (en)
Inventor
Daniel Cano
William James Michie Jr
Original Assignee
Union Carbide Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Union Carbide Corp filed Critical Union Carbide Corp
Publication of BR8901711A publication Critical patent/BR8901711A/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4743—Insulin-like growth factor binding protein
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Zoology (AREA)
  • Cardiology (AREA)
  • Urology & Nephrology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Dermatology (AREA)
  • Diabetes (AREA)
  • Toxicology (AREA)
  • Vascular Medicine (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Pulmonology (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Polymerisation Methods In General (AREA)
  • Transition And Organic Metals Composition Catalysts For Addition Polymerization (AREA)
BR898901711A 1988-04-12 1989-04-11 Aperfeicoamento no processo para a polimerizacao em leito fluido de alfaolefinas BR8901711A (pt)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US18075988A 1988-04-12 1988-04-12

Publications (1)

Publication Number Publication Date
BR8901711A true BR8901711A (pt) 1989-11-21

Family

ID=22661666

Family Applications (1)

Application Number Title Priority Date Filing Date
BR898901711A BR8901711A (pt) 1988-04-12 1989-04-11 Aperfeicoamento no processo para a polimerizacao em leito fluido de alfaolefinas

Country Status (7)

Country Link
EP (1) EP0418230B1 (pt)
JP (1) JPH03504597A (pt)
AT (1) ATE132164T1 (pt)
AU (1) AU1955388A (pt)
BR (1) BR8901711A (pt)
DE (1) DE3854842T2 (pt)
WO (1) WO1989009792A1 (pt)

Families Citing this family (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5258287A (en) * 1988-03-22 1993-11-02 Genentech, Inc. DNA encoding and methods of production of insulin-like growth factor binding protein BP53
US5324820A (en) * 1988-07-15 1994-06-28 Central Sydney Area Health Service Acid-labile subunit (ALS) of insulin-like growth factor binding protein complex
CA1341598C (en) * 1988-07-15 2009-09-29 Central Sydney Area Health Service Acid-labile sub-unit (als) of insulin-like growth factor binding proteincomplex
US6465423B1 (en) 1988-07-15 2002-10-15 Central Sydney Area Health Service Acid-labile subunit (ALS) of insulin-like growth factor binding protein complex
GB8826451D0 (en) * 1988-11-11 1988-12-14 Sandoz Ltd Improvements in/relating to organic compounds
IL92816A0 (en) * 1988-12-22 1990-09-17 Biogrowth Inc Recombinant dna molecules,hosts,processes and human somatomedin carrier protein-like polypeptides
US5126324A (en) * 1990-06-07 1992-06-30 Genentech, Inc. Method of enhancing growth in patients using combination therapy
IE913032A1 (en) * 1990-08-28 1992-03-11 Chiron Corp New insulin-like growth factor binding protein (igfbp-4)
US5212074A (en) * 1990-08-28 1993-05-18 Chiron Corporation Genetic material encoding new insulin-like growth factor binding protein igfbp-6
US5210017A (en) * 1990-11-19 1993-05-11 Genentech, Inc. Ligand-mediated immunofunctional hormone binding protein assay method
US6326154B1 (en) 1990-11-19 2001-12-04 Genentech, Inc. Ligand-mediated immunofunctional hormone binding protein assay method
CA2100083A1 (en) 1991-01-08 1992-07-09 Michael C. Kiefer Insulin-like growth factor binding protein
US5187151A (en) * 1991-02-12 1993-02-16 Genentech, Inc. Use of binding protein with igf-i as an anabolic growth promoting agent
JPH08509595A (ja) 1992-11-04 1996-10-15 カイロン コーポレイション 細胞分裂促進活性を有する短縮型インスリン様成長因子結合タンパク質
US6124259A (en) * 1993-01-28 2000-09-26 Celtrix Pharmaceuticals, Inc. Method for treating ophthalmic disorders with IGFBP
AU6626794A (en) * 1993-04-07 1994-10-24 Amgen Boulder Inc. Methods of using insulin-like growth factor binding proteins
US6420518B1 (en) 1997-04-04 2002-07-16 Genetech, Inc. Insulin-like growth factor agonist molecules
US6121416A (en) 1997-04-04 2000-09-19 Genentech, Inc. Insulin-like growth factor agonist molecules
DK1141014T3 (da) 1999-01-06 2005-04-11 Genentech Inc Insulinlignende vækstfaktor (IGF) i mutantvariant
JP2002535967A (ja) 1999-01-06 2002-10-29 ジェネンテック・インコーポレーテッド インシュリン様成長因子（ｉｇｆ）ｉ変異体
AU2001263215A1 (en) 2000-05-16 2001-11-26 Genentech Inc. Method for treating cartilage disorders
EP1401476A4 (en) 2001-03-14 2006-03-08 Genentech Inc IGF ANTAGONIST PEPTIDES
HUE027218T2 (en) 2003-09-12 2016-10-28 Ipsen Biopharmaceuticals Inc Methods for Treatment of IGF-1 (Insulin-like Growth Factor 1) Deficiency
AU2004278311A1 (en) 2003-10-03 2005-04-14 Genentech, Inc. IGF binding proteins
SG11202002088TA (en) 2017-09-11 2020-04-29 Shire Human Genetic Therapies Methods and compositions for treating chronic lung diseases
EP4228676B1 (en) 2020-10-19 2025-01-08 Oak Hill Bio Limited Compositions suitable for use in neonates
EP4466281A1 (en) 2022-01-19 2024-11-27 Oak Hill Bio Limited Compositions and methods for reducing oxidation of igf?1/igfbp
WO2023242440A1 (en) 2022-06-17 2023-12-21 Oak Hill Bio Limited Treament of lungs in infants
WO2023242442A1 (en) 2022-06-17 2023-12-21 Oak Hill Bio Limited Method of maturing/differentiating neurons and/or modulating the vagus nerve
WO2023242439A1 (en) 2022-06-17 2023-12-21 Oak Hill Bio Limited Vascular stabilisation (preterm infants)
CN120882420A (zh) 2023-02-14 2025-10-31 奥克希尔生物有限公司 Gi组织中愈合失调的治疗

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4394443A (en) * 1980-12-18 1983-07-19 Yale University Method for cloning genes
CA1209501A (en) * 1982-09-16 1986-08-12 Nikos Panayotatos Expression vector
EP0308500B1 (en) * 1987-04-06 1993-06-16 Celtrix Pharmaceuticals, Inc. Human somatomedin carrier protein subunits and process for producing them
DK131988A (da) * 1988-03-11 1989-09-12 Erasmus University Igf-bindingsprotein, dna-struktur, der koder for igf-bindingsproteinet og vektor indeholdende denne dna-struktur

Also Published As

Publication number Publication date
EP0418230A1 (en) 1991-03-27
DE3854842D1 (de) 1996-02-08
JPH03504597A (ja) 1991-10-09
DE3854842T2 (de) 1996-06-13
WO1989009792A1 (en) 1989-10-19
EP0418230A4 (en) 1991-10-23
AU1955388A (en) 1989-11-03
EP0418230B1 (en) 1995-12-27
ATE132164T1 (de) 1996-01-15

Similar Documents

Publication Publication Date Title
BR8901711A (pt) Aperfeicoamento no processo para a polimerizacao em leito fluido de alfaolefinas
FI963246A7 (fi) Geeniterapiassa käytettävä isäntävektorijärjestelmä
ATA105892A (de) Nagellack zur behandlung von onychomykosis enthaltend terbinafine
DE69429904D1 (de) Verfahren und System zum Vermitteln von tragbare Chipkarten verwendenden Transaktionen
DK1489097T3 (da) Hæmmere af humant plasmin, der er afledt af kunitz-domæner, og nukleinsyrer, der koder for samme
DK0572688T3 (da) Peptider, med organ-beskyttende aktivitet, fremgangsmåde til deres fremstilling og deres anvendelse ved terapi
FI954805L (fi) Menetelmiä insuliininkaltaisen kasvutekijän sitojaproteiinien käyttämiseksi
MX9203519A (es) Metodo de recombinacion para la produccion de inhibidores de proteasa de serina y secuencias de adn utiles para los mismos.
DK568287A (da) Relativt lavmolekylaere peptider og deres anvendelse som renininhibitorer
DE68923481D1 (de) Verfahren zum Behandeln von Sojabohnen.
NO980299D0 (no) Cytokinproduksjonsinhibitorer, preparater derav og deres anvendelse i medisin, samt fremgangsmåter for deres identifikasjon
DE69121982D1 (de) Wärmebehandlungsverfahren für Stahl, insbesondere von Stahl für Federn
NO169819C (no) Fremgangsmaate for fremstilling av hybrid polypeptid og dna-molekyl for bruk i denne
DE3584029D1 (de) Expressionsvektoren, dns-fragmente, peptide, wirte und verfahren zur herstellung von peptiden.
IL108584A0 (en) Cloning of interferon - alpha beta binding protein
DE69200991D1 (de) Grundierung für Nagellacke sowie dessen Verfahren.
DE69534738D1 (de) Leukocyten-aktivierender Faktor
DE68917536D1 (de) Methode zur Reduktion von aromatischen Amino-Gruppen.
ATE279521T1 (de) Regulierende nukleinsaeuresequenzen und verwendungen
FI970230L (fi) Menetelmä proteiinien, kuten yhdistelmä-DNA-hirudiinin tai -epidermaalisen kasvutekijän laskostamiseksi
ITRM930135A0 (it) Propulsore personale cingolato portatile in particolare per sciatori.
GB9604518D0 (en) Novel compounds
ATE107475T1 (de) Verfahren zum gerben von proteinsubstanzen, insbesondere pflanzliche proteinsubstanzen sowie ölige proteine und nach diesem verfahren hergestellte gegerbte proteinsubstanzen.
DK661389D0 (da) Dna-sekvens, som koder for placentaspecifikt protein pp11, dens isolering og anvendelse
DE59003909D1 (de) Verfahren zur nachbehandlung von holzschliff.

Legal Events

Date Code Title Description
FB19 Grant procedure suspended (art. 19)
FC Decision: refusal